Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about ACRV, unsubscribe in one click. Privacy
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| Wee1/PKMYT1 Inhibitor ACR-2316 | Specific Advanced Solid Tumors | Phase 1/2 · NCT06667141 | Recruiting |
| Prexasertib (ACR-368) | Head and Neck Squamous Cell Carcinoma | Phase 2 · NCT06597565 | Recruiting |
Also used in these trials (approved or third-party drugs, not ACRV's own candidates): Gemcitabine Hydrochloride.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
ACRV holds $90M in cash and short-term investments (as of Jun 30, 2026) and burns about $17.7M/quarter from operations, an estimated runway of 15.2 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure: 72 · High
Based on the Company’s current operating plan and existing cash, cash 8 equivalents, and investments, the Company has determined that there is substantial doubt regarding its ability to continue as a going concern within one year after the date that these condensed consolidated financial statements are issued.10-Q, Nov 2026
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when ACRV files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| Peter Blume-Jensen President and CEO, Director |
Insider | 2,615,911 | 6.10% | 2026-08-25 |
| Sands Capital Life Sciences Pulse Fund I | 5%+ holder (13G) | 2,289,271 | 5.33% | 2026-06-30 |
| Sands Capital Alternatives, LLC | Institution (13F) | 2,122,605 | 4.95% | 2025-12-31 |
| Kenneth Griffin | Institution (13G, 5%+) | 1,721,867 | 4.01% | 2025-11-14 |
| Citadel Advisors Llc | Institution (13F) | 1,641,884 | 3.83% | 2025-12-31 |
| Wellington Management Group, LLP | Institution (13F) | 888,130 | 2.07% | 2025-12-31 |
| Vanguard Group Inc | Institution (13F) | 698,857 | 1.63% | 2025-12-31 |
| Renaissance Technologies, LLC | Institution (13F) | 634,169 | 1.48% | 2025-12-31 |
| Two Sigma Investments, LP | Institution (13F) | 585,069 | 1.36% | 2025-12-31 |
| Acadian Asset Management. LLC | Institution (13F) | 581,208 | 1.35% | 2025-12-31 |
| Marshall Wace LLP | Institution (13F) | 496,081 | 1.16% | 2025-12-31 |
| RA CAPITAL MANAGEMENT, L.P. Director, 10% owner · +20,275 options |
Insider | 426,302 | 0.99% | 2026-05-18 |
Share count 42,911,680 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest (13F quarter ending 2025-12-31). Sources have different dates, so the split is approximate. Source: SEC EDGAR.
| Trade date | Insider | Transaction | Shares | Price | Owned after |
|---|---|---|---|---|---|
| 2026-08-31 filed 2026-09-02 |
Levin Michaela |
Award (A) | 30,000 | – | 30,000 |
| 2026-08-31 filed 2026-09-02 |
Levin Michaela |
Option award (A) | 130,000 | – | – |
| 2026-08-25 filed 2026-08-27 |
Blume-Jensen Peter |
Sale (S) | 14,036 | $2.21 | 2,230,052 |
| 2026-08-18 filed 2026-08-20 |
Peterson Katharine |
Sale (S) | 101 | $2.01 | 18,033 |
| 2026-08-18 filed 2026-08-20 |
Miller Mary |
Sale (S) | 185 | $2.01 | 82,009 |
Only open-market purchases (P) and sales (S) are trading decisions. Awards (A), option exercises (M) and tax withholding (F) are compensation mechanics. Source: SEC Form 4.
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for ACRV and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →